bromodomain inhibitor8

Bromodomain inhibitor-8 is an inhibitor of BET bromodomain used to treat autoimmune and inflammatory diseases.

PKG inhibitor peptide TFA (82801-73-8 free base) is an inhibitor of ATP-competitive cGMP-dependent protein kinase (PKG).

Tubulin inhibitor 8 is an inhibitor of tubulin and various cancer cell lines and inhibits tubulin polymerisation and K562 cell growth with an IC50 of 0.73 μM and 14 nM respectively.

GSK-3β inhibitor 8 (GSK3β Inhibitor XVIII) is a potent and selective GSK-3β inhibitor with an IC50 value of 64 nM.GSK-3β inhibitor 8 is a thienopyrimidine derivative that negatively regulates the Wnt signaling pathway and stimulates β-cell proliferation.

SIRT5 inhibitor 8 (compound 10) is a competitive inhibitor of sirtuin SIRT5 with an IC50 of 5.38 μM and exhibits anticancer potential [1].

Bromodomain Inhibitor-12 Edisylate (example 303) serves as a bromodomain inhibitor applicable to autoimmune and inflammatory disease research [1].

Tuberculosis inhibitor 8 (compound 3b), a 3-methoxy-2-phenylimidazo[1,2-b]pyridazine derivative, exhibits potent activity against both Mycobacterium tuberculosis and Mycobacterium marinum with an MIC 90 of 0.69 μM [1].

TRPM4 inhibitor 8 is an inhibitor of Transient receptor potential melastatin 4(TRPM4) which contributes to viability, migration, cell cycle shift, and adhesion.

Bromodomain inhibitor-9 is an inhibitor of Bromodomains that selectively inhibits the activity of BRD4-1 with a Kd value of 12 nM. Bromodomain inhibitor-9 can be used in studies of diseases related to systemic or lipid metabolism, tissue inflammation, fibrosis, or chronic autoimmune diseases.

α-Synuclein inhibitor 8 effectively impedes α-Synuclein aggregation and disaggregation with an IC50 of 2.5 µM, demonstrating substantial reduction in neuronal inclusion formation, which contributes to reparative effects in damaged neurons and symptomatic improvement in Parkinson’s disease (PD)-like models. The compound also exhibits high antioxidant activity and low cytotoxicity [1].

C-Myc Inhibitor 8 is an effective compound for cancer research, inhibiting cell viability across a range of cancer types and demonstrating growth suppression in human prostate and lung cancers within mouse models. This inhibitor specifically targets the c-Myc pathway, showcasing its potential utility in oncological studies.

JNK3 Inhibitor-8 is a potent, selective, and orally active inhibitor that can cross the blood-brain barrier, targeting JNK3 with IC50 values of 21 nM for JNK3, 2203 nM for JNK2, and >10000 nM for JNK1. This compound demonstrates significant neuroprotective effects and holds promise for Alzheimer’s disease (AD) research [1].

Topoisomerase I inhibitor 8, a hexacyclic analogue of camptothecin, is also a potent inhibitor of topoisomerase I and is toxic to tumour cells.

Bromodomain Inhibitor-12 (example 303) is a research compound utilized in the study of autoimmune and inflammatory diseases [1].

BET Bromodomain Inhibitor 3 is a BET bromodomain inhibitor with an inhibitory Ki value of >40 µM against BrdT. It is utilized in research related to contraception, cancer, and heart disease [1].

mTOR inhibitor-8 is a potent mTOR inhibitor and autophagy inducer with antiviral and antitumor activity. mTOR inhibitor-8 inhibits the growth of A549 cells, which can be used to study non-small cell lung cancer.

PI3K/mTOR Inhibitor-8 is a dual inhibitor of PI3K (PI3Kα IC50: 0.46 nM) and mTOR (mTOR IC50: 12 nM). PI3K/mTOR Inhibitor-8 blocks the cell cycle of HCT-116 cells in G1/S phase and induces apoptosis. apoptosis).

ERK1 2 inhibitor 8 is a potent ERK inhibitor, targeting ERK2 with an IC50 of 0.48 nM.

ATX inhibitor 8 is an inhibitor of the autocrine motor factor Autotaxin (ATX).

BET bromodomain inhibitor 1 is an orally active, selective inhibitor of bromodomain and extra-terminal (BET) proteins, specifically inhibiting BRD4 with an IC50 of 2.6 nM. It also demonstrates high affinities towards BRD2(2), BRD3(2), BRD4(1), BRD4(2), and BRDT(2) with Kd values of 1.3 nM, 1.0 nM, 3.0 nM, 1.6 nM, and 2.1 nM, respectively. This compound exhibits anti-cancer activity.

BET bromodomain inhibitor 2 is a potent inhibitor of the BET-type bromodomain with an IC50 of 14.1 μM.

MMP-8 Inhibitor I is a selective inhibitor of the neutrophil collagenase matrix metalloproteinase-8 (MMP-8) with an IC50 value of 4 nM.

Pim-1 kinase inhibitor 8 is a potent Pim-1 kinase inhibitor with anticancer activity and can effectively inhibit cell migration.Pim-1 kinase inhibitor 8 is cytotoxic to MCF-7 and HepG2 cells, and is a candidate compound for breast cancer research.

URAT1 Inhibitor 8 (example 247) serves as a highly potent inhibitor of URAT1, demonstrating an IC50 value of 0.001 μM. It is applicable in the study of gout [1].

FGFR1 inhibitor-8 (Compound 9), an FGFR1 inhibitor with an IC50 of 0.5 nM, binds to the ATP-binding pocket of FGFR1 and exhibits anticancer activity [1].

RIP1 Kinase Inhibitor 8 (Compound 77), a potent and highly selective dihydropyrazole (DHP) RIP1 kinase inhibitor, exhibits an IC50 of 20 nM and effectively prevents necrotic cell death. It also demonstrates a favorable pharmacokinetic profile across multiple species [1].

Aurora kinase inhibitor-8 (highly selective) inhibits Aurora kinase.

HIV-1 inhibitor-8 is a potent, orally active, low toxicity HIV-1 non-nucleoside reverse transcriptase inhibitor (NNRTI). HIV-1 inhibitor-8 is capable of acting on WT HIV-1 reverse transcriptase (IC50: 0.081 μM). HIV-1 inhibitor-8 exhibited potent antiviral effects against various HIV-1 strains with EC50 values of 4.44-54.5 nM.

HIV-1 integrase inhibitor 8 is an inhibitor of HIV-1 integrase, a critical enzyme necessary for the integration step in HIV replication [1].

ATM Inhibitor-8 (Compound 10r) is a potent, selective, and orally active ATM inhibitor with anti-tumor activity, characterized by an IC50 value of 1.15 nM [1].

Carbonic anhydrase inhibitor 8 (compound R-13) is a potent human carbonic anhydrase (hCA) with K i values of 60.7 nM, 320.7 nM, and 2298 nM for hCA I, hCA II, and hCA IV, respectively.

Bromodomain inhibitor-10 (compound 128) is a highly potent bromodomain activity inhibitor, exhibiting strong binding affinity with Kd values of 15.0 nM and 2500 nM for BRD4-1 and BRD4-2, respectively. It also effectively inhibits the production of IL12p40 [1].

KRAS inhibitor-8 is a potent inhibitor of the mutated KRAS G12C protein.

Chitin synthase inhibitor 8 is a chitin synthase (CHS) inhibitor with broad-spectrum antifungal properties, suitable for research on fungal infections.

Topoisomerase II inhibitor 8 (compound 22) is a potent inhibitor of topoisomerase II (IC50 = 0.52 μM) [1] and exhibits strong anti-proliferative activities, arresting the cell cycle at the G2 M phase.

BET bromodomain inhibitor is a potent BET inhibitor.

Competitive inhibitor of cGMP-dependent protein kinase (PKG); analog of a substrate peptide corresponding to a phosphorylation site of histone H2B. Competes with synthetic substrates (Ki = 86 mM) but does not inhibit phosphorylation of intact histones by